Antibody Pretargeting Based on Bioorthogonal Click Chemistry for Cancer Imaging and Targeted Radionuclide Therapy
| Autor: | Aurélie Rondon, Françoise Degoul |
|---|---|
| Přispěvatelé: | Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Institut National de la Santé et de la Recherche Médicale (INSERM) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Immunoconjugates
medicine.medical_treatment [SDV]Life Sciences [q-bio] Targeted radionuclide therapy Biomedical Engineering Pharmaceutical Science Bioengineering [SDV.CAN]Life Sciences [q-bio]/Cancer 02 engineering and technology Cancer imaging 01 natural sciences Cyclooctanes Heterocyclic Compounds 1-Ring Neoplasms medicine Animals Humans Pretargeting Pharmacology 010405 organic chemistry Chemistry Organic Chemistry Antibodies Monoclonal Cancer Radioimmunotherapy 021001 nanoscience & nanotechnology medicine.disease 0104 chemical sciences 3. Good health Click chemistry Cancer research Click Chemistry Radiopharmaceuticals Bioorthogonal chemistry 0210 nano-technology Preclinical imaging Biotechnology |
| Zdroj: | Bioconjugate Chemistry Bioconjugate Chemistry, American Chemical Society, 2019, 31 (2), pp.159-173. ⟨10.1021/acs.bioconjchem.9b00761⟩ |
| ISSN: | 1043-1802 1520-4812 |
| DOI: | 10.1021/acs.bioconjchem.9b00761⟩ |
| Popis: | International audience; Bioorthogonal click chemistry-employing antibody-conjugated trans-cyclooctenes (TCO) and tetrazine (Tz)-based radioligands able to covalently bind in vivo-appeared recently as a potential alternative to circumvent the hematotoxicity induced by radioimmunotherapy of solid tumors. This Review focuses on the recent advances concerning TCO/Tz pretargeting in both cancer imaging and targeted-radionuclide therapy for prospective clinical transfer. We exhaustively identified 25 PubMed publications reporting preclinical imaging and 5 therapy studies with full mAbs as targeting vectors, since its first application in 2010. The fast, safe, modulable, and specific TCO/Tz pretargeting showed high potential as a theranostic tool to get more personalized and precise cancer care. The recent optimizations reported here highlighted a possible first clinical evaluation of IEDDA pretargeting in the coming years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|